Skip to main content
SpringerLink
Log in

Interferon-beta responders and non-responders. A biological approach

  • Multiple Sclerosis: The Management of Non-Responders
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The therapeutic benefits of interferon-beta are limited, as some patients with multiple sclerosis (MS) do not respond to therapy. Based on their biological characteristics, non-responsive patients can be divided into three subgroups: genetic, pharmacological and pathogenetic non-responders. In order to tailor the best treatment in both newly diagnosed MS patients and those already receiving treatment, the neurologist must carefully consider the risk of treating non-responders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rio J, Nos C, Tintoré M et al (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352

    Article  PubMed  Google Scholar 

  2. Gilli F, Valentino P, Sala A et al (2007) Correlation between gene expression of interferon alpha/beta receptor and inducibility of four interferon stimulated genes in peripheral blood mononuclear cells from multiple sclerosis patients. Mult Scler 13[Suppl 2]:S65,P227

    Google Scholar 

  3. Mathurin P, Xiong S, Kharbanda KK et al (2002) IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 282:G981–G990

    PubMed  Google Scholar 

  4. Karussis D, Biermann LD, Bohlega S et al; the International Working Group for Treatment Optimization in MS (2006) A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 13:61–71

    Article  PubMed  CAS  Google Scholar 

  5. Vallittu AM, Halminen M, Peltoniemi J et al; Finnish Beta-Interferon Study Group (2002) Neutralizing antibodies reduce MxA protein induction in interferon beta-1a-treated MS patients. Neurology 58:1786–1790

    PubMed  Google Scholar 

  6. Gilli F, Bertolotto A, Sala A et al (2004) Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 127:259–268

    Article  PubMed  Google Scholar 

  7. Gilli F, Bertolotto A, Sala A et al (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158:195–203

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro Riferimento Regionale Sclerosi Multipla (CRESM) & Neurobiologia Clinica, AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano, TO, Italy

    Antonio Bertolotto & Francesca Gilli

Authors
  1. Antonio Bertolotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Gilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Bertolotto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertolotto, A., Gilli, F. Interferon-beta responders and non-responders. A biological approach. Neurol Sci 29 (Suppl 2), 216–217 (2008). https://doi.org/10.1007/s10072-008-0941-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-008-0941-2

Keywords

Search

Navigation